Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer

Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer

With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment str...

Full description

Bibliographic Details
Main Authors: Benlin HUANG, Yong DUAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
Immune checkpoint inhibitors
Small cell lung cancer
PD-1
PD-L1
CTLA-4
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07

Similar Items